Artwork

Content provided by K&L Gates LLP and L Gates. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by K&L Gates LLP and L Gates or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Highlights from FDA Regulatory Developments in Clinical Trials: 2023 Recap and 2024 Forecast

15:54
 
Share
 

Manage episode 404839551 series 1533910
Content provided by K&L Gates LLP and L Gates. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by K&L Gates LLP and L Gates or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode, Rebecca Schaefer, Michael Hinckle, and Elisabeth Lewis summarize FDA regulatory developments from 2023 and what to expect in 2024 as it relates to clinical research. They discuss the significance of the decentralized clinical trials guidance documents, highlights of the Informed Consent Guidance document, the impacts of FDA’s final rule on IRB waivers of consent, the IRB review of individual patient expanded access submissions, and the potential effects of the new proposed rule for lab developed tests.

  continue reading

100 episodes

Artwork
iconShare
 
Manage episode 404839551 series 1533910
Content provided by K&L Gates LLP and L Gates. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by K&L Gates LLP and L Gates or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode, Rebecca Schaefer, Michael Hinckle, and Elisabeth Lewis summarize FDA regulatory developments from 2023 and what to expect in 2024 as it relates to clinical research. They discuss the significance of the decentralized clinical trials guidance documents, highlights of the Informed Consent Guidance document, the impacts of FDA’s final rule on IRB waivers of consent, the IRB review of individual patient expanded access submissions, and the potential effects of the new proposed rule for lab developed tests.

  continue reading

100 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide